Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer

On November 18, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported new preclinical data demonstrating the potential of atebimetinib to serve as a backbone for combinations with multiple classes of anticancer agents. The findings, generated using both animal models and three-dimensional (3D) tumor models of pancreatic ductal adenocarcinoma (PDAC), identify multiple synergistic combination strategies and provide further support for atebimetinib’s potential to play a central role as a MAPK pathway backbone for combinations in pancreatic cancer and beyond. The data will be presented in a Poster Spotlight presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We believe atebimetinib’s long survival, excellent tolerability profile, and broad all-comers activity reported in Phase 2 make it the increasingly likely backbone of choice for combinations with both chemotherapies and emerging agents that target subsets of pancreatic cancer patients," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Building on our recently announced collaboration targeting CLDN18.2-positive pancreatic cancer, these new findings demonstrate synergistic activity with multiple classes of emerging agents including PRMT5 inhibitors for tumors with MTAP deletions, as well as KRAS G12D and G12V inhibitors for tumors with those particular mutations. The data presented today strengthen the scientific rationale for developing atebimetinib as a backbone therapy in combination with additional agents targeting patient subsets in pancreatic cancer and suggest a broad set of potential opportunities to deploy atebimetinib in multiple combinations across multiple lines of therapy, starting with the exciting chemotherapy combination we are evaluating in our Phase 3 study, MAPKeeper 301."

The research being presented today includes results from Immuneering’s humanized 3D tumor growth assay (3D-TGA) platform, which previously identified the potential for atebimetinib to enhance the activity of gemcitabine and nab-paclitaxel (GnP), a combination subsequently supported by encouraging clinical results in the Company’s Phase 2a study in first-line pancreatic cancer. This combination is now being evaluated in MAPKeeper 301, a phase 3 pivotal trial evaluating atebimetinib plus mGnP versus GnP.

Key findings include:

Broad synergy with targeted therapies: Atebimetinib demonstrated synergistic activity in preclinical PDAC models when combined with multiple mutation-specific KRAS inhibitors targeting KRAS G12C, G12D, and G12V, PRMT5 inhibitors, as well as agents targeting BRAF, EGFR, and other components of the MAPK signaling pathway.
In vivo validation of KRAS inhibitor combinations: Combination activity with a KRAS G12D-targeted agent was confirmed in an in vivo pancreatic cancer xenograft model, providing additional evidence of atebimetinib’s potential to enhance the activity of mutant-selective RAS-targeted therapies.
Activity with complementary cancer treatment mechanisms: Atebimetinib demonstrated promising combination activity with agents targeting pathways involved in cancer cell survival, proliferation, and resistance, including GSK-3β, PI3K/mTOR, CDK4/6, and other targets, as well as multiple chemotherapy agents.
Biomarker-driven treatment opportunities: Combination activity was particularly pronounced in models with specific genomic characteristics, including matching KRAS mutations for vertical pathway inhibition and MTAP deletion for combinations involving PRMT5 inhibitors. These findings support the potential for atebimetinib to serve as a broad, all-comers MAPK backbone combined with specific agents targeted at particular patient populations.
Potential utility across multiple lines of therapy: The results support a proposed treatment strategy in which atebimetinib could be deployed in combination with chemotherapy in the first-line setting, potentially combined with mutant-selective RAS inhibitors in subsequent treatment, and paired with biomarker-selected therapies following RAS inhibitor exposure.

Presentation Details:
Title: Patient-aligned 3D tumor models identify biomarker-enriched atebimetinib (IMM-1-104) combination strategies in pancreatic ductal adenocarcinoma.
Abstract Number: 22
Poster Number: PB-003
Presenter: Anna Travesa
Date: Thursday, November 19, 2026

The poster is available on the publications section of Immuneering’s website.

(Press release, Immuneering, NOV 18, 2026, View Source [SID1234674919])